Ildong Pharmaceutical, which is seeking to introduce the new migraine drug Reyvow in Korea, has decided not to accept the upper limit offered by the Pharmaceutical Benefit Evaluation Committee of the Health Insurance Review and Assessment Service. The measure was decided in consultation with Lilly, who holds the global copyright of the drug, and they say they will continue to make efforts to register their salaries. On the 7th of last month, the Pharmaceutical Benefit Evaluation Committee of the HIRA Committee reviewed Ildong Pharmaceutical's acute migraine treatment Reyvow 50mg and Reyvow100mg and judged that the benefit was appropriate if it was accepted below the evaluation amount. If Ildong Pharmaceutical accepted